VISIBILITE: Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work

Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle (Other)
Overall Status
Recruiting
CT.gov ID
NCT05056350
Collaborator
(none)
25
1
1
19.5
1.3

Study Details

Study Description

Brief Summary

The diagnosis of breast cancer and the treatments implemented have a significant impact on the professional situation.

Maintaining employment and/or reintegration into working life are therefore major issues for cancer patients.

This trial proposes to study the feasibility of a support/coaching program for a return to work in patients after breast cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaires
  • Other: back to work coaching
N/A

Detailed Description

This study involves patients with breast cancer at the end of their adjuvant treatment.

The aim of this study is to evaluate the feasibility of a support program for an adapted return to work of these patients.

This back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops.

The evolution of quality of life, psychological distress and perceptions concerning work will also be evaluated through assessments and questionnaires before (inclusion) and after the support program [1 month (+/- 7 days) and 6 months (+/- 1 month) after the final individual assessment].

The study also aims to estimate the recruitment rate in the study and to assess the satisfaction of this support program.

Finally, the impact of this support program on the return to work will be described.

This initial study will eventually lead to a larger research protocol on the effectiveness of the program, using a randomized controlled trial design.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work
Actual Study Start Date :
Sep 13, 2021
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Assessment of the feasibility and impact of a back-to-work support program

questionnaires, back to work coaching

Other: Questionnaires
Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire

Other: back to work coaching
Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops

Outcome Measures

Primary Outcome Measures

  1. Patient adherence of a coaching program for an adapted return to work [through study completion, an average of 1 year]

    Assessment of the feasibility of a support program for an adapted return to work in patients with breast cancer, after their adjuvant treatment. Feasibility is defined by the proportion of patients who have adhered to the support program, with the patient attending at least 5 of the 7 proposed sessions.

Secondary Outcome Measures

  1. Impact of the support program on the return to work [At 1 month and at 6 months]

    Description of the impact of the support program on return to work, defined as any return to work, regardless of the number of hours worked by the patient before diagnosis. The description will be made by the number of patients with a return to work (resumption of previous activity or new professional activity) and, if applicable, at what date.

  2. Estimation of recruitment rate in the study [At inclusion]

    Estimation of recruitment rate in the study by the proportion of patients agreeing to participate in the program among eligible patients

  3. Evolution of perceptions regarding work importance [AT inclusion, at 1 month and 6 months]

    The score on a visual analog "work importance" scale, ranging from 0 to 10 (10 indicating a high level of importance).

  4. Evolution of Work Ability [AT inclusion, at 1 month and 6 months]

    by the Work Ability Index, on a scale of 0 to 10 (10 indicating significant ability).

  5. Evolution of self-efficacy [AT inclusion, at 1 month and 6 months]

    The self-efficacy score , obtained on the Lagerveld et al. (2010) to 11 items (with a high score indicating a high degree of self-efficacy.

  6. Satisfaction of the support program Satisfaction of the support program [At 1 month and at 6 months]

    Assessment of the satisfaction of the support program by coaching. Assessment by program satisfaction score on a visual analog scale ranging from 1 to 10 (10 indicating high satisfaction)

  7. Quality of life (QoL) [At inclusion, at 1 month and at 6 months]

    By the QoL score obtained on the EORTC QLQ-C30 & EORTC QLQ-BR23 questionnaires

  8. Evolution of the psychological distress of patients [At inclusion, at 1 month and at 6 months]

    Description of the evolution of the psychological distress of patients. Measured by HADS scale (Hospital Anxiety and Depression Scale). The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale. Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T). Each item is rated on a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), for a total score ranging from 0-21 for each subscale. The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥18 years

  • Patients cared at the Montpellier Cancer Institute (ICM) for non-metastatic breast cancer who have received adjuvant treatment (radiotherapy and/or chemotherapy)

  • Patient who has completed adjuvant treatment, except for hormonotherapy

  • Patient practicing a profession at the time of diagnosis, looking for a job or in professional retraining at the time of diagnosis

  • Patient expressing spontaneously or on request of the oncologist physical or psychological difficulties in the professional field

  • Patient wishing to be accompanied for an adapted return to her current job or for a return to a new more adapted job

  • Patient who signed the informed consent after informed information by her clinician

Exclusion Criteria:
  • Metastatic breast cancer or any other cancer within the last 5 years

  • Patient who haven't completed herr adjuvant treatment (chemotherapy and/or radiotherapy)

  • Psychological condition requiring therapeutic support (objectified by the Mini International Neuropsychiatric Interview test (MINI) by identifying a Diagnostic and Statistical Manual (DSM)-IV Axis I psychiatric disorder (American Psychiatric Association, 1994) Sheehan et al., 1998) with the patient's refusal of adequate psychiatric treatment (medicated or not) at the time of inclusion in the study

  • Severely impaired global cognitive functioning (objectified by an adjusted score of less than 20 on the Montreal Cognitive Assessment (MoCA) test)

  • Physical inability to answer questionnaires

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut du Cancer de Montpellier Montpellier France 34298

Sponsors and Collaborators

  • Institut du Cancer de Montpellier - Val d'Aurelle

Investigators

  • Study Chair: Estelle Guerdoux, Dr, Institut du Cancer de Montpellier

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Institut du Cancer de Montpellier - Val d'Aurelle
ClinicalTrials.gov Identifier:
NCT05056350
Other Study ID Numbers:
  • PROICM 2020-07 VIS
  • 2020-A00955-34
First Posted:
Sep 24, 2021
Last Update Posted:
Jan 24, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institut du Cancer de Montpellier - Val d'Aurelle
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 24, 2022